Olivares Sevilla, Marta
[UCL]
Neyrinck, Audrey M.
[UCL]
Pötgens, Sarah
[UCL]
Beaumont, Martin
[UCL]
Salazar, Nuria
Cani, Patrice D.
[UCL]
Bindels, Laure B.
[UCL]
Delzenne, Nathalie M.
[UCL]
(eng)
AIMS/HYPOTHESIS: Dipeptidyl peptidase 4 (DPP-4) inhibitors are agents designed to increase the half-life of incretins. Although they are administered orally, little is known about their effects on the gut microbiota and functions, despite the fact that some bacteria present in the gut microbiota exhibit DPP-4-like activity. Our objective was to study the impact of the DPP-4 inhibitor vildagliptin on gut functions and the intestinal ecosystem in a murine model of obesity induced by a Western diet (WD).
METHODS: Twenty seven male C57BL/6J mice were randomised to receive a control diet, a WD (45% kJ from fat and 17% kJ from sucrose) or a WD + vildagliptin (0.6 mg/ml in drinking water) for 8 weeks.
RESULTS: Vildagliptin significantly reduced DPP-4 activity in the caecal content and faeces. Vildagliptin impacted on the composition of the gut microbiota and its metabolic activity. It mainly decreased Oscillibacter spp. (a direct effect independent of DPP-4 activity was shown on cultured O. valericigenes), increased Lactobacillus spp. and propionate, and reduced the ligands of Toll-like receptors 2 and 4. Vildagliptin protected against the reductions in crypt depth and ileal expression of antimicrobial peptides induced by the WD. In the liver, the expression of immune cell populations (Cd3g and Cd11c [also known as Itgax]) and cytokines was decreased in the WD + vildagliptin-fed mice compared with the WD-fed group. Ex vivo exposure of precision-cut liver slices to vildagliptin showed that this response was not related to a direct effect of the drug on the liver tissue.
CONCLUSIONS/INTERPRETATION: Our study is the first to consider the DPP-4-like activity of the gut microbiota as a target of DPP-4 inhibition. We propose that vildagliptin exerts beneficial effects at the intestinal level in association with modulation of gut microbiota, with consequences for hepatic immunity. If relevant in humans, this could open new therapeutic uses of DPP-4 inhibition to tackle gut dysfunctions in different pathophysiological contexts.
DATA AVAILABILITY: The sequences used for analysis can be found in the MG-RAST database under the project name MYNEWGUT3.
- Seino Yutaka, Fukushima Mitsuo, Yabe Daisuke, GIP and GLP-1, the two incretin hormones: Similarities and differences : Similarities and differences of GIP and GLP-1, 10.1111/j.2040-1124.2010.00022.x
- Mulvihill Erin E., Drucker Daniel J., Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors, 10.1210/er.2014-1035
- Lee Sang Ah, Kim Young Ree, Yang Eun Jin, Kwon Eun-Jeong, Kim Sun Hyung, Kang Sung Ha, Park Doek Bae, Oh Byung-Chul, Kim Jinseok, Heo Sang Taek, Koh Gwanpyo, Lee Dae Ho, CD26/DPP4 Levels in Peripheral Blood and T Cells in Patients With Type 2 Diabetes Mellitus, 10.1210/jc.2012-4288
- Stengel Andreas, Goebel-Stengel Miriam, Teuffel Pauline, Hofmann Tobias, Buße Petra, Kobelt Peter, Rose Matthias, Klapp Burghard F., Obese patients have higher circulating protein levels of dipeptidyl peptidase IV, 10.1016/j.peptides.2014.09.006
- Sell H., Bluher M., Kloting N., Schlich R., Willems M., Ruppe F., Knoefel W. T., Dietrich A., Fielding B. A., Arner P., Frayn K. N., Eckel J., Adipose Dipeptidyl Peptidase-4 and Obesity: Correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro, 10.2337/dc13-0496
- Kushwaha R.N., Haq W., Katti S.B., Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective, 10.2174/0929867321666140915143309
- Waget Aurélie, Cabou Cendrine, Masseboeuf Myriam, Cattan Pierre, Armanet Mattieu, Karaca Mélis, Castel Julien, Garret Celine, Payros Gaëlle, Maida Adriano, Sulpice Thierry, Holst Jens J., Drucker Daniel J., Magnan Christophe, Burcelin Rémy, Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice, 10.1210/en.2011-0286
- Mulvihill Erin E., Varin Elodie M., Gladanac Bojana, Campbell Jonathan E., Ussher John R., Baggio Laurie L., Yusta Bernardo, Ayala Jennifer, Burmeister Melissa A., Matthews Dianne, Bang K.W. Annie, Ayala Julio E., Drucker Daniel J., Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis, 10.1016/j.cmet.2016.10.007
- Mortier Anneleen, Gouwy Mieke, Van Damme Jo, Proost Paul, Struyf Sofie, CD26/dipeptidylpeptidase IV-chemokine interactions: double-edged regulation of inflammation and tumor biology, 10.1189/jlb.3mr0915-401r
- Yazbeck Roger, Howarth Gordon S., Abbott Catherine A., Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?, 10.1016/j.tips.2009.08.003
- Hartmann B., Thulesen J., Kissow H., Thulesen S., Orskov C., Ropke C., Poulsen S. S., Holst J. J., Dipeptidyl Peptidase IV Inhibition Enhances the Intestinotrophic Effect of Glucagon-Like Peptide-2 in Rats and Mice1, 10.1210/endo.141.11.7752
- Wronkowitz Nina, Görgens Sven W., Romacho Tania, Villalobos Laura A., Sánchez-Ferrer Carlos F., Peiró Concepción, Sell Henrike, Eckel Jürgen, Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2, 10.1016/j.bbadis.2014.06.004
- Lee DS, Lee ES, Alam MM et al (2016) Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate. Metabolism 65:89–101
- Makdissi Antoine, Ghanim Husam, Vora Mehul, Green Kelly, Abuaysheh Sanaa, Chaudhuri Ajay, Dhindsa Sandeep, Dandona Paresh, Sitagliptin Exerts an Antinflammatory Action, 10.1210/jc.2012-1544
- Ta Nga N., Li Yanchun, Schuyler Corinne A., Lopes-Virella Maria F., Huang Yan, DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes, 10.1016/j.atherosclerosis.2010.08.064
- Ervinna Nasib, Mita Tomoya, Yasunari Eisuke, Azuma Kosuke, Tanaka Rica, Fujimura Satoshi, Sukmawati Dewi, Nomiyama Takashi, Kanazawa Akio, Kawamori Ryuzo, Fujitani Yoshio, Watada Hirotaka, Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice, 10.1210/en.2012-1855
- Santaolalla Rebeca, Abreu Maria T., Innate immunity in the small intestine : , 10.1097/mog.0b013e3283506559
- He Yan-Ling, Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin : , 10.2165/11598080-000000000-00000
- Delzenne Nathalie M., Neyrinck Audrey M., Bäckhed Fredrik, Cani Patrice D., Targeting gut microbiota in obesity: effects of prebiotics and probiotics, 10.1038/nrendo.2011.126
- Shin Na-Ri, Lee June-Chul, Lee Hae-Youn, Kim Min-Soo, Whon Tae Woong, Lee Myung-Shik, Bae Jin-Woo, An increase in theAkkermansiaspp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice, 10.1136/gutjnl-2012-303839
- Walker N. D., Cloning and functional expression of dipeptidyl peptidase IV from the ruminal bacterium Prevotella albensis M384T, 10.1099/mic.0.26119-0
- Stressler Timo, Eisele Thomas, Schlayer Michael, Lutz-Wahl Sabine, Fischer Lutz, Characterization of the Recombinant Exopeptidases PepX and PepN from Lactobacillus helveticus ATCC 12046 Important for Food Protein Hydrolysis, 10.1371/journal.pone.0070055
- Sanz Y., Toldra F., Purification and Characterization of an X-Prolyl-Dipeptidyl Peptidase from Lactobacillus sakei, 10.1128/aem.67.4.1815-1820.2001
- Zeng Z., Luo J.Y., Zuo F.L., Yu R., Zhang Y., Ma H.Q., Chen S.W., Bifidobacteria possess inhibitory activity against dipeptidyl peptidase-IV, 10.1111/lam.12510
- Zeng Zhu, Luo Junyi, Zuo Fanglei, Zhang Ying, Ma Huiqin, Chen Shangwu, Screening for potential novel probiotic Lactobacillus strains based on high dipeptidyl peptidase IV and α-glucosidase inhibitory activity, 10.1016/j.jff.2015.11.030
- Zhang Qian, Xiao Xinhua, Li Ming, Yu Miao, Ping Fan, Zheng Jia, Wang Tong, Wang Xiaojing, Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats, 10.1371/journal.pone.0184735
- Grasset Estelle, Puel Anthony, Charpentier Julie, Collet Xavier, Christensen Jeffrey E., Tercé François, Burcelin Rémy, A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism, 10.1016/j.cmet.2017.04.013
- Bindels Laure B, Neyrinck Audrey M, Claus Sandrine P, Le Roy Caroline I, Grangette Corinne, Pot Bruno, Martinez Inés, Walter Jens, Cani Patrice D, Delzenne Nathalie M, Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia, 10.1038/ismej.2015.209
- Bindels Laure B., Segura Munoz Rafael R., Gomes-Neto João Carlos, Mutemberezi Valentin, Martínez Inés, Salazar Nuria, Cody Elizabeth A., Quintero-Villegas Maria I., Kittana Hatem, de los Reyes-Gavilán Clara G, Schmaltz Robert J., Muccioli Giulio G., Walter Jens, Ramer-Tait Amanda E., Resistant starch can improve insulin sensitivity independently of the gut microbiota, 10.1186/s40168-017-0230-5
- Salazar Nuria, Dewulf Evelyne M., Neyrinck Audrey M., Bindels Laure B., Cani Patrice D., Mahillon Jacques, de Vos Willem M., Thissen Jean-Paul, Gueimonde Miguel, de los Reyes-Gavilán Clara G., Delzenne Nathalie M., Inulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women, 10.1016/j.clnu.2014.06.001
- Neyrinck Audrey, Taminiau Bernard, Walgrave Hannah, Daube Georges, Cani Patrice, Bindels Laure, Delzenne Nathalie, Spirulina Protects against Hepatic Inflammation in Aging: An Effect Related to the Modulation of the Gut Microbiota?, 10.3390/nu9060633
- Neyrinck Audrey M., Alexiou Hélène, Delzenne Nathalie M., Kupffer Cell Activity Is Involved in the Hepatoprotective Effect of Dietary Oligofructose in Rats with Endotoxic Shock, 10.1093/jn/134.5.1124
- Neyrinck Audrey M, Gomez Cristina, Delzenne Nathalie M, 10.1186/1476-5926-2-s1-s45
- Suriano Francesco, Bindels Laure B., Verspreet Joran, Courtin Christophe M., Verbeke Kristin, Cani Patrice D., Neyrinck Audrey M., Delzenne Nathalie M., Fat binding capacity and modulation of the gut microbiota both determine the effect of wheat bran fractions on adiposity, 10.1038/s41598-017-05698-y
- Reichardt Nicole, Duncan Sylvia H, Young Pauline, Belenguer Alvaro, McWilliam Leitch Carol, Scott Karen P, Flint Harry J, Louis Petra, Phylogenetic distribution of three pathways for propionate production within the human gut microbiota, 10.1038/ismej.2014.14
- Cani P. D., Possemiers S., Van de Wiele T., Guiot Y., Everard A., Rottier O., Geurts L., Naslain D., Neyrinck A., Lambert D. M., Muccioli G. G., Delzenne N. M., Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability, 10.1136/gut.2008.165886
- Richards Paul, Pais Ramona, Habib Abdella M., Brighton Cheryl A., Yeo Giles S.H., Reimann Frank, Gribble Fiona M., High fat diet impairs the function of glucagon-like peptide-1 producing L-cells, 10.1016/j.peptides.2015.06.006
- Psichas A, Sleeth M L, Murphy K G, Brooks L, Bewick G A, Hanyaloglu A C, Ghatei M A, Bloom S R, Frost G, The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents, 10.1038/ijo.2014.153
- Vaishnava S., Behrendt C. L., Ismail A. S., Eckmann L., Hooper L. V., Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface, 10.1073/pnas.0808723105
- De Arpan, Pompilio Arianna, Francis Jenifer, Sutcliffe Iain C., Black Gary W., Lupidi Giulio, Petrelli Dezemona, Vitali Luca A., Antidiabetic “gliptins” affect biofilm formation by Streptococcus mutans, 10.1016/j.micres.2018.02.005
- Lam Yan Y., Ha Connie W. Y., Campbell Craig R., Mitchell Andrew J., Dinudom Anuwat, Oscarsson Jan, Cook David I., Hunt Nicholas H., Caterson Ian D., Holmes Andrew J., Storlien Len H., Increased Gut Permeability and Microbiota Change Associate with Mesenteric Fat Inflammation and Metabolic Dysfunction in Diet-Induced Obese Mice, 10.1371/journal.pone.0034233
- Moya-Pérez Angela, Neef Alexander, Sanz Yolanda, Bifidobacterium pseudocatenulatum CECT 7765 Reduces Obesity-Associated Inflammation by Restoring the Lymphocyte-Macrophage Balance and Gut Microbiota Structure in High-Fat Diet-Fed Mice, 10.1371/journal.pone.0126976
- Geurts Lucie, Lazarevic Vladimir, Derrien Muriel, Everard Amandine, Van Roye Marie, Knauf Claude, Valet Philippe, Girard Myriam, Muccioli Giulio G., François Patrice, de Vos Willem M., Schrenzel Jacques, Delzenne Nathalie M., Cani Patrice D., Altered Gut Microbiota and Endocannabinoid System Tone in Obese and Diabetic Leptin-Resistant Mice: Impact on Apelin Regulation in Adipose Tissue, 10.3389/fmicb.2011.00149
- Scaldaferri Franco, Pizzoferrato Marco, Gerardi Viviana, Lopetuso Loris, Gasbarrini Antonio, The Gut Barrier : New Acquisitions and Therapeutic Approaches, 10.1097/mcg.0b013e31826ae849
- Everard Amandine, Lazarevic Vladimir, Gaïa Nadia, Johansson Maria, Ståhlman Marcus, Backhed Fredrik, Delzenne Nathalie M, Schrenzel Jacques, François Patrice, Cani Patrice D, Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity, 10.1038/ismej.2014.45
- Lee Seung-Jun, Lee Jennifer, Li Karen K., Holland Dianne, Maughan Heather, Guttman David S., Yusta Bernardo, Drucker Daniel J., Disruption of the MurineGlp2rImpairs Paneth Cell Function and Increases Susceptibility to Small Bowel Enteritis, 10.1210/en.2011-1954
- Drucker D. J., Erlich P., Asa S. L., Brubaker P. L., Induction of intestinal epithelial proliferation by glucagon-like peptide 2., 10.1073/pnas.93.15.7911
- Briand François, Brousseau Emmanuel, Quinsat Marjolaine, Burcelin Rémy, Sulpice Thierry, Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model, 10.1016/j.ejphar.2017.11.021
- Sheng Lili, Jena Prasant Kumar, Hu Ying, Liu Hui-Xin, Nagar Nidhi, Kalanetra Karen M, French Samuel William, French Samuel Wheeler, Mills David A, Wan Yu-Jui Yvonne, Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation : Butyrate and hepatitis, 10.1002/path.4983
- Scheen A. J., Pharmacokinetics of dipeptidylpeptidase-4 inhibitors, 10.1111/j.1463-1326.2010.01212.x
Bibliographic reference |
Olivares Sevilla, Marta ; Neyrinck, Audrey M. ; Pötgens, Sarah ; Beaumont, Martin ; Salazar, Nuria ; et. al. The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice.. In: Diabetologia : clinical and experimental diabetes and metabolism, Vol. 61, no. 8, p. 1838-1848 (2018) |
Permanent URL |
http://hdl.handle.net/2078.1/199597 |